Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06587490 · ClinicalTrials.gov registry record · Phase 3
Total RadIoTherapy of Oligometastatic caNcerS
A Phase 3 study of Oligometastatic Malignant Solid Neoplasm, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT06587490 is a Phase 3 study of Oligometastatic Malignant Solid Neoplasm that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 300 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06587490, a Phase 3 study of Oligometastatic Malignant Solid Neoplasm, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase III non-blinded randomized study evaluating patients with oligometastatic cancers (up to 10 metastases). Subjects are randomized 1:1 to stereotactic ablative radiotherapy (SABR) plus standard of care therapies versus standard of care therapies alone. The investigators will measure progression-free survival at 2 years based on the hypothesis that subjects treated with SABR plus standard of care will not experience disease progression for a longer period of time than subjects treated with standard of care alone. The investigators will also measure overall survival and safety of SABR, as well as biomarkers that may help predict, in the future, who will benefit from the SABR treatment.
Conditions Studied
Interventions
- RADIATION stereotactic ablative radiotherapy
Study Locations (1)
California
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-11-12 |
| Est. Completion | 2034-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06587490
The ClinicalTrials.gov registry entry for NCT06587490 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oligometastatic Malignant Solid Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which stereotactic ablative radiotherapy is the first listed.
NCT06587490 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06587490 about?
NCT06587490 is a clinical study titled "Total RadIoTherapy of Oligometastatic caNcerS". This is a Phase III non-blinded randomized study evaluating patients with oligometastatic cancers (up to 10 metastases). Subjects are randomized 1:1 to stereotactic ablative radiotherapy (SABR) plus standard of care therapies versus standard of care therapies alone. The investigators will measure pr...
What is the current status of trial NCT06587490?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2024-11-12. Estimated completion is 2034-11.
What conditions does trial NCT06587490 study?
This clinical trial studies the following conditions: Oligometastatic Malignant Solid Neoplasm.
What interventions are being tested in trial NCT06587490?
The interventions under investigation include: stereotactic ablative radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT06587490?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06587490 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oligometastatic Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.